Close Menu
Two years after switching its technology focus, drug-discovery firm Calibrant Biosystems last week announced it will use its Gemini platform with the Cleveland Clinic to identify protein networks linked to an aggressive form of brain tumor.
 
The deal, which could further validate the Gemini technology — Calibrant’s sole research platform — aims to identify protein networks and novel therapeutics involved in gliobastoma multiforme.
 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

IBM security researchers warn of a phishing campaign targeted at organizations involved in the distribution of SARS-CoV-2 vaccines, the Verge reports.

The Illinois police have cut the number of DNA tests waiting to be run in about half, CBS Chicago reports.

A researcher accused of smuggling research materials out of the US has pleaded guilty to making false statements, according to the Associated Press.

In Science this week: gene expression signature linked to nonalcoholic fatty liver disease progression, and more.